Stock listing

NASDAQ:IAM Iambic Therapeutics, Inc. Stock

Home listing (NASDAQ) of Iambic Therapeutics, Inc.

Follow Iambic Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:IAM

$13.11 USD -1.65 (-11.2%)

Close on Nov 20, 2026

Past month -30.7% · daily closes, Oct 15, 2026 – Nov 20, 2026, adjusted for splits
Day range
$12.77 – $14.00 USDNov 20, 2026
Volume
281,909 sharesNov 20, 2026
Market cap
$621.4M USDAt the close on Nov 20, 2026 · price × 47.40M shares outstanding
Traded on an average day
$11.91M USDMedian day 480,276 shares · last 3 months, Oct 15, 2026 – Nov 20, 2026
Iambic Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:IAM · Home$13.11 USD-1.65 (-11.2%)281,909$13.98$14.00$12.77$14.76Close on Nov 20, 2026

Daily closes

Last 3 months, Oct 15, 2026 – Nov 20, 2026 · NASDAQ:IAM · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$13.11-1.65-11.2%$13.98$14.00$12.77281,909
$14.76+0.54+3.8%$15.00$15.42$14.10376,015
$14.22+2.37+20.0%$11.97$14.71$11.58481,652
$11.85-1.25-9.5%$12.69$12.94$11.35456,377
$13.10-1.74-11.7%$14.90$15.06$12.68277,675
$14.84-0.545-3.5%$15.39$15.39$14.02488,739
$15.39+0.605+4.1%$14.87$15.85$13.96364,830
$14.78+1.40+10.5%$14.47$15.01$12.80867,820
$13.38+3.21+31.6%$10.06$13.47$9.90899,208
$10.17-1.47-12.6%$11.52$11.84$9.60671,700
$11.64-1.76-13.1%$13.16$13.22$10.55751,300
$13.40-0.09-0.7%$13.80$13.96$13.15293,400
$13.49+0.53+4.1%$13.10$13.74$12.43220,300
$12.96-0.47-3.5%$13.43$13.55$12.02402,700
$13.43-0.85-6.0%$13.10$13.57$12.39476,700
$14.28-0.50-3.4%$14.79$14.96$13.76270,100
$14.78+0.78+5.6%$13.84$16.50$13.60925,300
$14.00-0.41-2.8%$14.41$14.90$13.51439,700
$14.41+0.15+1.1%$14.40$15.25$14.00149,000
$14.26-0.41-2.8%$14.50$14.64$13.02609,600
$14.67-1.13-7.2%$15.40$15.47$14.50495,900
$15.80-0.21-1.3%$15.50$17.06$15.00478,900
$16.01-0.33-2.0%$16.31$17.50$15.00980,600
$16.34-7.47-31.4%$21.00$21.54$14.102,382,700
$23.81+4.90+25.9%$19.31$25.00$19.312,964,900
$18.91——$16.15$19.70$16.152,009,400
Ticker
NASDAQ:IAM
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Iambic Therapeutics, Inc. news

Iambic Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
2 in the last 12 months · 2 in all · newest Nov 9, 2026 · oldest 2026

Where Iambic Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:IAM · Home listing · This pageNASDAQUnited StatesUSD
BOATS:IAMBOATSUnited StatesUSD

Valuation

EV/sales 39.2× against a median of 5.5×: 6th lowest of 8 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$369.4M USD
P/E
Loss
EV/sales
39.2×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
Not reported
Operating margin
−873.6%
Net margin
−820.0%
Debt to equity
Negative equity
Beta vs S&P 500
Under 6 months of closes

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Iambic Therapeutics, Inc. · NASDAQ:IAMUS$621.4MUS$369.4Mn/a39.2×n/an/a−820.0%n/an/a
Shouyao Holdings Beijing Co. Ltd. Class A · SSE:688197US$647.2MUS$565.0Mn/a37.8×n/a6.8×−18.6%0.0×n/a
Prime Medicine, Inc. · NASDAQ:PRMEUS$645.8MUS$695.1Mn/a98.4×n/a76.5×n/a13.1×2.28
Sagimet Biosciences Inc. - Series A · NASDAQ:SGMTUS$638.7MUS$404.3Mn/an/an/a2.6×n/a0.0×1.96
Gubra A/S · OMXCOP:GUBRAUS$638.5MUS$533.6M2.6×1.4×1.7×4.2×64.1%0.2×n/a
Kura Oncology, Inc. · NASDAQ:KURAUS$634.9MUS$152.6Mn/a1.9×n/a35.4×−369.3%0.6×1.30
Alphamab Oncology · HKEX:9966US$628.9MUS$454.7Mn/a5.5×n/a2.5×−20.1%0.2×n/a
Janux Therapeutics, Inc. · NASDAQ:JANXUS$616.7M−US$308.6Mn/a−13.3×n/a0.7×−428.7%0.0×0.95
Olema Pharmaceuticals, Inc. · NASDAQ:OLMAUS$615.0MUS$204.6Mn/an/an/a1.7×n/a0.0×1.25
Alebund Pharmaceuticals (Jiangsu) Limited Class H · HKEX:9637US$608.9MUS$483.6Mn/a106×n/a2.9×n/a0.4×n/a
Annexon, Inc. · NASDAQ:ANNXUS$587.7MUS$423.7Mn/an/an/a4.1×n/a0.3×1.63
Median of the othersUS$631.9MUS$439.2M2.6×5.5×1.7×3.5×−20.1%0.2×1.47

Forecasts

3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
27.25 USD · Analysts' mean
EPS, year to Dec 2026
-3.51 · 3 analysts
Revenue, year to Dec 2026
75.87M · 4 analysts

Team and board

Officers

OfficerRole
Tom MillerCo-Founder and Chief Executive Officer
Michael SecoraChief Financial Officer and Chief Corporate Development Officer
Sunny ChangGeneral Counsel
Laurent GomezSenior Vice President and Head of Discovery
Matt WelbornSenior Vice President, Machine Learning
Fred ManbyCo-Founder and Chief Technology Officer
Neil JosephsonChief Medical Officer
Pete OlsonChief Scientific Officer

Board

DirectorRole
William RastetterBoard Chair
Evan RachlinBoard Member
Jacob VogelsteinBoard Member
Kurt von EmsterBoard Member
Mary TagliaferriBoard Member
Samit HirawatBoard Member
Shalini SharpBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 16, 2026 · Before open−9.5%

Open Events

IPO

Priced at US$16.00 a share on Oct 14, 2026.

Price
US$16.00 a share
Shares offered
9,375,000 shares of common stock
Offering size
US$150 million
Underwriters' option
Up to 1,406,250 more shares
Listing
IAM on the Nasdaq Global Select Market
Underwriters
J.P. Morgan, Jefferies, BofA Securities, Citigroup · In the order on the cover
Shares delivered
On or about Oct 16, 2026

Steps

StepWhen
Draft sent to the SEC in confidenceJul 24, 2026
Filed publiclySep 21, 2026
Amended onceOct 8, 2026
Shares registered with an exchangeOct 13, 2026
Declared effective by the SECOct 14, 2026
Final prospectus, with the priceOct 15, 2026

Open IPO · From the cover of the final prospectus (424B4) filed Oct 15, 2026

Financials

Annual, in USD

Income statement

LineFY2025FY2024
Revenue9.43M1.19M
Research and development77.5M45.7M
Selling, general and administrative14.2M9.38M
Operating income-82.3M-53.9M
Depreciation and amortization1.23M1.06M
EBITDA-81.1M-52.8M
Interest expense17.0K8.00K
Income before tax-77.3M-47.8M
Net income-77.3M-47.9M
Earnings per share, basic-1.63-1.01

Balance sheet

LineFY2025FY2024
Cash and equivalents180.5M141.6M
Receivables1.32M444.0K
Current assets183.6M143.9M
Total assets195.0M155.7M
Accounts payable3.32M2.88M
Current liabilities26.3M16.9M
Total liabilities381.6M268.0M
Shareholders' equity-186.6M-112.2M
Shares outstanding47.4M47.4M

Cash flow

LineFY2025FY2024
Cash from operations-58.8M-33.6M
Capital spending-1.28M-707.0K
Free cash flow-60.1M-34.3M
Cash from financing99.1M65.0M
Change in cash39.0M30.7M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 19, 2026Quarterly reportSEC
8-K · Current reportNov 16, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeNov 9, 2026Big-stake noticeSEC
4 · Change in ownershipOct 19, 2026Insider tradeSEC
4 · Change in ownershipOct 19, 2026Insider tradeSEC
4 · Change in ownershipOct 19, 2026Insider tradeSEC
4 · Change in ownershipOct 19, 2026Insider tradeSEC
4 · Change in ownershipOct 19, 2026Insider tradeSEC
8-K · Current reportOct 16, 2026Current reportSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
All 49 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 16, 2026Insider tradeSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
424B4 · ProspectusOct 15, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 15, 2026Other filingsSEC
3 · Initial statement of ownershipOct 14, 2026Insider tradeSEC
S-8 · Registration statement for employee plansOct 14, 2026Offer documentSEC
3 · Initial statement of ownershipOct 14, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 14, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 14, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 14, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 14, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 14, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 14, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 14, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 14, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 14, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 14, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 14, 2026Insider tradeSEC
CERT · Exchange's certificate of listingOct 14, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeOct 13, 2026Other filingsSEC
S-1/A · Registration statement, amendedOct 8, 2026Offer documentSEC
S-1 · Registration statementSep 21, 2026Offer documentSEC
DSep 9, 2026Other filingsSEC
DRS/A · Draft registration statement, amendedAug 28, 2026Offer documentSEC
DRS · Draft registration statementJul 24, 2026Offer documentSEC
DApr 8, 2026Other filingsSEC
DNov 21, 2025Other filingsSEC
D/AJun 6, 2024Other filingsSEC
D/AMay 7, 2024Other filingsSEC
DApr 25, 2024Other filingsSEC
DOct 12, 2023Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Iambic Therapeutics, Inc.’s releases

Common shares
47,400,796
Fully diluted
47,400,796

Fully diluted

LineShares
Common shares47,400,796

Share count over time

CountShares
Nov 22, 202647,400,796

Open Cap table

Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Rachlin Evan Lockwood
Director
Buy718,750USD 16.00US$11.5MOct 16, 2026

Big stakes

StakeStakeSharesDateFiling
Qatar Investment Authority5.80%2.8MOct 15, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
William H. Rastetter
Other companies: Dare Bioscience, Inc. (Chairman of the Board · Since at least Jun 30, 2026); Neurocrine Biosciences, Inc. (Director · Since at least May 21, 2026); Fate Therapeutics, Inc. (Chairman · Since at least May 5, 2026)
Board Chair · Since at least Oct 16, 2026
Shalini Sharp
Other companies: Neurocrine Biosciences, Inc. (Director · Since at least Apr 15, 2026)
Board Member · Since at least Nov 5, 2026
Evan RachlinBoard Member · Since at least Oct 16, 2026
Fred ManbyCo-Founder and Chief Technology Officer · Since at least Nov 4, 2026
Jacob VogelsteinDirector · Since at least Oct 16, 2026
Kurt von EmsterBoard Member · Since at least Nov 5, 2026
Laurent GomezSenior Vice President and Head of Discovery · Since at least Nov 4, 2026
Mary TagliaferriBoard Member · Since at least Nov 5, 2026
Matt WelbornSenior Vice President, Machine Learning · Since at least Nov 4, 2026
Michael SecoraCFO & Chief Corp Dev Ofcr · Since at least Oct 16, 2026
All 15 people
PersonSeat
Neil JosephsonChief Medical Officer · Since at least Oct 26, 2026
Pete OlsonChief Scientific Officer · Since at least Nov 4, 2026
Samit HirawatBoard Member · Since at least Nov 5, 2026
Sunny ChangGeneral Counsel · Since at least Nov 4, 2026
Tom MillerCo-Founder and Chief Executive Officer · Since at least Oct 26, 2026

Open People

Log in to ask 6ix AI your own questions about Iambic Therapeutics, Inc.